Federal court rejects PhRMA challenge to Medicare drug price negotiation

Fifth Circuit Delivers Another Setback to Pharma’s Push Against Medicare Drug Negotiation

Provpnadvice.com – The pharmaceutical industry’s prolonged legal assault on the federal government’s authority to negotiate drug prices for Medicare beneficiaries took another major blow on Wednesday, when the U.S. Court of Appeals for the Fifth Circuit upheld a lower court’s dismissal of a lawsuit brought by the Pharmaceutical Research and Manufacturers of America (PhRMA). The decision marks the latest in a string of judicial rulings that have consistently validated the drug-pricing mechanism created under the Inflation Reduction Act, signaling that courts across multiple circuits see little merit in the industry’s constitutional objections.

The Core Legal Question: Voluntary Participation

At the heart of the Fifth Circuit’s reasoning was a straightforward structural point: enrollment in Medicare and Medicaid is optional for drug manufacturers. Companies are under no obligation to route their products through the federal negotiation program if they find the resulting prices unacceptable. Because participation is a choice rather than a compulsion, the court held that manufacturers do not possess a constitutionally protected entitlement to dictate their own pricing terms when dealing with the government.

“We conclude that manufacturers lack a protected interest in selling to Medicare beneficiaries at a preferred price because participation in Medicare and Medicaid, and thus in the Program, is voluntary.”

The panel did acknowledge what it called the “financial importance” of Medicare as a revenue channel for pharmaceutical firms. Yet the judges drew a firm line between recognizing that economic significance and finding that financial pressure amounts to involuntary conscription into a pricing scheme. In their view, a company that walks away from the program simply forgoes a market segment; it is not being coerced into accepting unfavorable terms.

Procedural History and the District Court’s Earlier Ruling

The case had already been effectively decided at the trial level. Last year, U.S. District Judge David Alan Ezra granted summary judgment against PhRMA, reasoning that the plaintiffs could not establish a cognizable deprivation of a protected interest under the Due Process Clause. His language was categorical:

“[The plaintiffs] cannot demonstrate that the Program deprives them of a protected interest and therefore their Due Process Clause claim fails as a matter of law.”

The Fifth Circuit affirmed that determination, leaving no avenue for further appellate review within the circuit. For PhRMA, which represents roughly 2,000 member companies spanning large innovators and smaller generics firms, the loss removes one of the most prominent vehicles through which the industry has sought to dismantle the negotiation framework.

A Pattern of Judicial Rejection

This ruling does not stand alone. Multiple other suits filed by industry-aligned organizations and individual manufacturers have met the same fate. The U.S. Chamber of Commerce, along with named companies including Boehringer Ingelheim, AstraZeneca, and Merck, have each brought challenges that courts have dismissed on similar grounds. In May of this year, the Supreme Court declined to grant certiorari on a petition seeking review of the Medicare negotiation program, a move that effectively endorsed the lower courts’ unanimous rejection of the industry’s arguments and closed the door on further federal-court litigation at the highest level.

The cumulative effect is a judicial consensus: the Inflation Reduction Act’s negotiation mechanism, which empowers CMS to set prices for a growing list of drugs covered under Medicare Part D, withstands constitutional scrutiny. Manufacturers retain the option to sell outside the program, to negotiate separately with private insurers, or to adjust their product portfolios, but they cannot compel the government to pay a price they deem adequate.

Advocacy Groups Celebrate; Industry Faces Strategic Reassessment

Consumer-advocacy organizations reacted swiftly. Emma Sands, director of media and communications at Patients For Affordable Drugs, framed the outcome as a milestone in a long campaign:

“PhRMA has been at the center of the industry’s years-long, multi-million-dollar legal campaign to overturn Medicare negotiation. Now, they’ve lost one of their most significant challenges to the program to date. The Fifth Circuit rejected this sweeping constitutional attack, delivering the 25th courtroom victory for Medicare negotiation and the patients who fought for it.”

Peter Maybarduk, access-to-medicines director at the consumer-rights nonprofit Public Citizen, offered a broader characterization of the industry’s strategy and its ultimate failure:

“For years, drugmakers sought to sow doubt and find a sympathetic court, fighting something everyone wants, which is affordable medicine and a government that negotiates aggressively on Americans’ behalf. They failed.”

What the Ruling Means Going Forward

With the Fifth Circuit’s decision now on the books, the negotiation program’s legal footing is substantially reinforced across the majority of federal circuits. The practical implications for patients are direct: CMS can continue expanding the list of drugs subject to negotiated pricing without facing a credible constitutional injunction. For manufacturers, the ruling underscores that the only remaining levers are commercial ones—deciding which products to offer through the program, which to reserve for commercial channels, and how to structure launch strategies around the prospect of a government-negotiated price.

The decision also narrows the space for future litigation. Because the court grounded its holding in the voluntary nature of participation, any renewed challenge would need to identify a different constitutional hook or demonstrate that some specific provision of the program operates as a de facto compulsion. Given the Supreme Court’s earlier refusal to intervene, the probability of finding a receptive tribunal appears slim. For the roughly 60 million Americans enrolled in Medicare, the ruling removes a persistent source of uncertainty about whether the price-negotiation mechanism will survive long enough to deliver the savings Congress intended when it passed the Inflation Reduction Act in 2022.